Table 2.
Clinical and metabolic parameters and hormone levels after placebo and mifepristone administration
| Placebo | Mifepristone | P value | |
|---|---|---|---|
| Weight (kg) | 97.7 ± 16.3 | 97.4 ± 15.8 | 0.590 |
| Body mass index (kg/m2) | 32.4 ± 4.3 | 32.2 ± 3.9 | 0.390 |
| Systolic blood pressure (mmHg) | 121 ± 12 | 130 ± 13 | 0.009 |
| Diastolic blood pressure (mmHg) | 71 ± 10 | 77 ± 9 | 0.010 |
| Total cholesterol (mg/dL) | 177.3 ± 38.7 | 163.6 ± 41.9 | 0.004 |
| HDL cholesterol (mg/dL) | 44.9 ± 8.8 | 41.3 ± 11.9 | 0.010 |
| LDL cholesterol (mg/dL) | 101.9 ± 31.1 | 97.1 ± 34.6 | 0.10 |
| Triglycerides (mg/dL) | 151.9 ± 79.3 | 125.6 ± 65.6 | 0.002 |
| Total testosterone (ng/dL), male subjects [RR 262-1593] | 355.2 ± 124.1 | 235.2 ± 87.5 | 0.010 |
| Androstenedione (ng/dL) [RR men: 26-125; RR women 17-175] | 66.7 ± 41.7 | 109.9 ± 64.7 | 0.007 |
| DHEA sulfate (µg/mL) [RR men 0.80-5.6; RR women 0.35-4.3] | 0.82 ± 0.45 | 1.04 ± 0.64 | 0.004 |
| Urinary free cortisola (µg/24 h) [RR 5-45] | 25.3 ± 30.2 | 74.1 ± 75.3 | <0.001 |
Post-treatment values shown are unadjusted means ± SD. Posttreatment values were adjusted for baseline value and treatment group when used in mixed-model regression. P-values indicate significance for comparisons between mifepristone and placebo.
a Urine free cortisol was measured by liquid chromatography, tandem mass spectrometry; the reference range is 5 to 45 ug/24 h.